Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Dereck Tait; Mark Hatherill; Olivier Van Der Meeren; Ann M. Ginsberg; Elana van Brakel; Bruno Salaun; Thomas J. Scriba; Elaine Jacqueline Akité; Helen Ayles; Anne Bollaerts; Marie‐Ange Demoitié; Andreas H. Diacon; Thomas G. Evans; Paul Gillard; Elizabeth Hellström; James C. Innes; Maria Lempicki; Mookho Malahleha; Neil Martinson; Doris Mesia Vela; Monde Muyoyeta; Videlis Nduba; Thierry Pascal; Michèle Tameris; Friedrich Thienemann; Robert J. Wilkinson; François Roman

doi:10.1056/nejmoa1909953

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Among adults infected with M. tuberculosis, vaccination with M72/AS01E elicited an immune response and provided protection against progression to pulmonary tuberculosis disease for at least 3 years. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tait et al. (2019) studied this question.

synapsesocial.com/papers/69d99b64a1d151c65f684949 https://doi.org/10.1056/nejmoa1909953

View Full Paper

Ask AI

Bookmark

Share

Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Ask about this paper

Abstract

Discussion

Cite This Study

Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading